A comprehensive meta-analysis confirms tirzepatide, a dual GIP/GLP-1 receptor agonist, provides effective weight reduction across populations with and without diabetes. The systematic review highlights its robust efficacy and safety profile, marking it as a pivotal advancement in metabolic disease therapeutics and obesity treatment strategies.